Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems Inc. (NYSE: INSP) provides innovative neurostimulation solutions for obstructive sleep apnea (OSA) treatment. This news hub offers investors and healthcare professionals centralized access to official updates, including FDA milestones, clinical trial results, and strategic developments.
Track the company’s progress in advancing minimally invasive therapies through verified press releases, regulatory filings, and market expansion announcements. Key updates include earnings reports, partnership agreements, and advancements in OSA treatment technology.
Discover how Inspire Medical maintains compliance with global medical device standards while delivering clinically validated solutions. Content is organized chronologically for efficient research, with clear sourcing to ensure reliability.
Bookmark this page for real-time updates on INSP’s neurostimulation innovations and their impact on sleep medicine. For comprehensive analysis, combine these primary sources with third-party market commentary available across Stock Titan.
Inspire Medical Systems (NYSE: INSP) has announced its participation at the BofA Securities Health Care Conference 2023, scheduled for May 10, 2023, at 11:40 a.m. ET. The presentation will showcase its innovative solutions for obstructive sleep apnea, including the proprietary Inspire therapy, the only FDA-approved neurostimulation technology for treating moderate to severe cases. Interested parties can access the live webcast here. A replay will be available for two weeks on Inspire’s Investor website, which can be visited here.
Inspire Medical Systems (NYSE: INSP) is set to release its first-quarter 2023 financial results on May 2, 2023, after market close. A conference call will follow at 5:00 p.m. Eastern Time, where management will discuss results and recent business developments. Investors can access the call through the company’s Investor Relations webpage or via a direct link provided in the announcement. Inspire is known for its innovative Inspire therapy, the only FDA-approved neurostimulation treatment for moderate to severe obstructive sleep apnea, highlighting the company's focus on advancing medical technology in this specialized market.
Inspire Medical Systems (NYSE: INSP) announced FDA approval for its Inspire therapy to treat pediatric obstructive sleep apnea (OSA) in patients with Down syndrome aged 13 and older. This marks a significant expansion from its previous approval limited to adults. The therapy, validated by extensive clinical trials, offers a minimally invasive solution for children who cannot benefit from CPAP therapy. With support from key medical researchers and organizations, Inspire plans to educate healthcare providers on the new treatment option, enhancing access to care for this vulnerable population. Coverage from several payers, including Medicare, is expected to facilitate treatment.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
